ROSGQ (Rosetta Genomics) Forward Dividend Yield %: 0.00% (As of Jul. 08, 2026)


What is Rosetta Genomics Forward Dividend Yield %?

Rosetta Genomics ROSGQ Forward Dividend Yield % is 0.00% as of Jul. 08, 2026.

As of today (2026-07-08), the Forward Annual Dividend Yield of Rosetta Genomics is 0.00%.

As of today (2026-07-08), the Trailing Annual Dividend Yield of Rosetta Genomics is 0.00%.

ROSGQ's Forward Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.11
* Ranked among companies with meaningful Forward Dividend Yield % only.

Rosetta Genomics's Dividends per Share for the six months ended in Jun. 2017 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Rosetta Genomics  (OTCPK:ROSGQ) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Rosetta Genomics Forward Dividend Yield % Related Terms

ROSGQ vs TEAR, IDTA, ABMC: Forward Dividend Yield % Comparison

For the Diagnostics & Research subindustry, Rosetta Genomics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rosetta Genomics Forward Dividend Yield % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Forward Dividend Yield % falls into.


Rosetta Genomics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Rosetta Genomics (ROSGQ) has a Forward Dividend Yield % of 0.00% as of Jul. 08, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Rosetta Genomics and its competitors.
Is Rosetta Genomics' Forward Dividend Yield % too high?
Rosetta Genomics' current Forward Dividend Yield % is 0.00%.
How does Rosetta Genomics' Forward Dividend Yield % compare to TEAR and IDTA?
Rosetta Genomics' Forward Dividend Yield % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. The industry median Forward Dividend Yield % is 2.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Diagnostics & Research company?
The median Forward Dividend Yield % among Medical Diagnostics & Research companies is 2.11, based on 63 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Rosetta Genomics and its competitors. For the Medical Diagnostics & Research industry, the median Forward Dividend Yield % is 2.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rosetta Genomics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rosetta Genomics stock overvalued right now?
Rosetta Genomics (ROSGQ) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Rosetta Genomics (ROSGQ), the current Forward Dividend Yield % is 0.00% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rosetta Genomics Business Description

Address 10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.